



Vol. I No. XVIII 21 June - 27 June

Company Spotlight

- **Globelmmune** (Broomfield) was named to Fierce Biotech's 2008 Fierce 15 List! What makes it Fierce: Globelmmune's third round of financing last fall was its biggest, \$41.2M, bringing its total venture haul to north of \$88M. Wexford capital led the round and Celgene, Boston Life Science Venture, Morgenthaler Ventures and Biogen Idec all participated. The money takes the company to a crucial inflection point: Phase II data that determines if the company's platform technology can deliver the kind of T-cell response it is looking for. Globelmmune has three mid-stage studies underway to determine if its genetically modified recombinant yeast can induce T-cells to attack pancreatic cancer and hepatitis C.
- **Replidyne** (Broomfield) has terminated their licensing deal with Asubio Pharma for its lead drug candidate Faropenem and subsequently is expecting a charge of approximately \$4.1M. Recall, Replidyne discontinued enrollment in a late-stage study testing its faropenem medoxomil oral antibiotic as a treatment for patients with acute chronic bronchitis due to an inability to secure a partner for the clinical program. Concomitant to the terminated license agreement is termination of the supply agreement with Nippon Soda Co. Engineering costs and delayed compensation fees comprise a portion of the expected \$4.1M charges.
- **Quark Pharmaceuticals** (Boulder) received approval from the FDA to initiate Phase I human trials on DGF_i, a kidney transplant drug. The trial is expected to start enrollment in 2H08. The drug candidate addresses the delayed graft function syndrome affecting transplant patients. The DGF_i drug candidate leverages siRNA technology to inhibit activity of p53.

Financings

- **Global Med Technologies** (Denver) creator of software systems for blood transfusion and laboratory work, completed its \$11.5M acquisition of a Inlog S.A., a software company based in France as well as its German subsidiary. InLog's primary product is blood donor center and transfusion information management systems, used at 700 sites in 15 countries.

People

- **Governor Bill Ritter** made an appearance on NBC's "Meet the Press" this past Sunday morning. Tom Brokaw hosted the show from Jackson Hole, Wyo., where Gov. Ritter attended the annual Western Governors Association conference. Gov. Ritter and Wyoming Gov. Dave Freudenthal will appear on one of the show's segments together.
- Viral Genetics a subsidiary V-Clip Pharmaceuticals has expanded the existing Exclusive License Agreement with the University of Colorado by obtaining the rights for treatment and detection of several forms of cancer including lung, breast, leukemia, and others, multiple sclerosis, diabetes, rheumatoid arthritis, malaria and several other diseases using technology developed by Professor **M. Karen Newell, Ph.D.**, who is the Clement and Margaret Merkert-endowed Professor of Biology at the University of Colorado, Colorado Springs. The existing Exclusive License Agreement was previously restricted to HIV/AIDS, Herpes, and Hepatitis C.

- **Gia Voelz, Ph.D.**, the University of Colorado Department of Molecular Cell and Developmental Biology's newest Assistant Professor, is profiled in a recent Journal of Cell Biology feature entitled: "Gia Voeltz: Shaping Ideas about ER Shape". In it she discusses both personal and professional forces that have shaped her career and how her ideas are shaping the discussion about membrane topology. Read the article ([HERE](#)).

Square Pegs

- On the heels of last weeks publications from Families USA's Global Health Initiative report, ranking Colorado No. 4 among states that generated the most economic activity per dollar of funding from the NIH, and the 2008 Milken Institute State Technology and Science Index ranking Colorado 3rd, trailing only Massachusetts and Maryland, based on technology and science assets and the ability to lever said assets for economic growth, comes now from [Genome Technology](#) a report on **Best Biotech Places and Emerging Clusters**. In addition to highlighting Colorado as a premiere emerging cluster the other US-based emerging clusters included Texas, Tennessee, Kansas, Alabama and New York. Clearly Colorado has made tremendous strides of late and remains affixed on a very promising trajectory!
- A twenty-year celebration of researchers from the **Colorado State University Cancer Supercluster** and the **University of Colorado** was held. The two entities have partnered on research that has lead to breakthroughs in cancer treatment for humans and companion animals. University Colorado Cancer Center is the Rocky Mountain region's National Cancer Institute-designated comprehensive cancer center, one of just 40 in the United States. UCCC, a consortium of six member institutions and eight affiliated organizations, exists to allow Colorado cancer scientists and clinicians to share equipment, faculty, technicians and expertise with one another, rather than duplicating efforts.
- The Nation's bioscience industry continues to grow as states and regions vie to attract high-wage jobs according to the Battelle study, "**Technology, Talent and Capital: State Bioscience Initiatives 2008**." The study presents data on national, state and metropolitan bioscience employment and growth trends during 2001 to 2006. It also examines a series of additional key performance metrics and describes state policies and programs designed to accelerate the growth of the biosciences. Read the Colorado portion of the report ([HERE](#)).